Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

医学 内科学 乳腺癌 肿瘤科 雌激素受体 比例危险模型 阶段(地层学) 癌症 疾病 化疗 妇科 古生物学 生物
作者
Dimitrios Zardavas,Luc te Marvelde,Roger L. Milne,Debora Fumagalli,George Fountzilas,Vassiliki Kotoula,Evangelia Razis,George Papaxoinis,Heikki Joensuu,Mary Ellen Moynahan,Bryan T. Hennessy,Ivan Bièche,Lao H. Saal,Olle Stål,Barry Iacopetta,Jeanette Dupont Jensen,Sandra A. O’Toole,Elena López‐Knowles,Mattia Barbaraeschi,Shinzaburo Noguchi
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:36 (10): 981-990 被引量:121
标识
DOI:10.1200/jco.2017.74.8301
摘要

Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes. Results Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P < .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P < .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P < .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); > 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS ( P = .043), but not for the DDFS and OS end points. Conclusion In this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
加油女王完成签到,获得积分10
刚刚
科研通AI6.3应助1771408007采纳,获得10
刚刚
wei发布了新的文献求助10
2秒前
xiaohu完成签到 ,获得积分10
2秒前
爆米花应助梦中偶遇山寨采纳,获得10
2秒前
3秒前
丰富的雪糕完成签到,获得积分10
3秒前
xiaozhang发布了新的文献求助10
3秒前
YueLongZ完成签到,获得积分10
4秒前
5秒前
5秒前
momo完成签到,获得积分20
5秒前
神明发布了新的文献求助10
5秒前
QIQI发布了新的文献求助10
5秒前
小凉发布了新的文献求助20
6秒前
6秒前
布丁发布了新的文献求助10
6秒前
6秒前
7秒前
whale完成签到,获得积分10
7秒前
科研通AI6.1应助Sunnig盈采纳,获得10
7秒前
Hello应助张秉环采纳,获得10
7秒前
Ou完成签到,获得积分10
8秒前
9秒前
香蕉觅云应助giggle采纳,获得10
9秒前
活力的青枫完成签到 ,获得积分10
10秒前
是小程啊发布了新的文献求助10
10秒前
想喝三碗粥完成签到,获得积分10
10秒前
1111发布了新的文献求助50
10秒前
12秒前
12秒前
孙哈哈发布了新的文献求助10
13秒前
纯白发布了新的文献求助10
13秒前
LL发布了新的文献求助30
14秒前
听雨白陌发布了新的文献求助10
14秒前
15秒前
16秒前
桐桐应助完美栾采纳,获得10
16秒前
TristanW完成签到,获得积分10
17秒前
Owen应助下雨采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6019897
求助须知:如何正确求助?哪些是违规求助? 7615343
关于积分的说明 16163262
捐赠科研通 5167628
什么是DOI,文献DOI怎么找? 2765714
邀请新用户注册赠送积分活动 1747574
关于科研通互助平台的介绍 1635713